DUBLIN--(BUSINESS WIRE)--The "Global Chemotherapy induced neutropenia Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global Chemotherapy induced neutropenia market was valued at US$ 7.71 billion in 2016, and is expected to reach US$ 12.56 billion by 2025, expanding at a CAGR of 5.6% from 2017 to 2025.
Global chemotherapy induced neutropenia market will show significant growth during forecast period due to some factors such as rising incidence of different forms of cancer, extensive R&D activities in development of novel therapeutics and upsurge funding by the government for life threatening disease in developed countries would drive the market growth during forecast period.
For the purpose of study market is segmented on the basis of treatment type (antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion and splenectomy procedure) and geography.
It is studied that currently, colony-stimulating factor therapy is preferably used in market because colony-stimulating factor such as granulocyte-CSF (G-CSF) and granulocyte-macrophage CSF (GM-CSF) have ability to stimulate and accelerate the production of one or more cell lines in the bone marrow, furthermore regulatory guidelines recommend prophylactic G-CSF treatment for chemotherapy patients with an overall high risk (=20%) is driving the growth of G-CSF market globally.
In the base year 2016, North America held largest share in global chemotherapy induced neutropenia market, United States held largest market share in North America due to factors such as upsurge funding by government and increase in incidence of different forms of cancer. It is estimated that Asia Pacific will show highest growth during forecast period due to increasing healthcare awareness and increasing prevalence of different forms of cancer would fuel market growth.
Key Market Movements:
- Factors such as rising incidence of different forms of cancer, extensive research and development activities and upsurge funding by the government for treatment are expected to drive the growth of chemotherapy induced neutropenia market during forecast period.
- However, some factors such as lower healthcare awareness in some developing countries, lack of medication availability in most poor income countries may negatively impacting the growth of chemotherapy induced neutropenia market.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Chemotherapy Induced Neutropenia Market Analysis
Chapter 4 Global Chemotherapy Induced Neutropenia Market, by Treatment Type
Chapter 5 Global Chemotherapy Induced Neutropenia Market, by Geography
Chapter 6 Company Profiles
- Baxter International
- Biogenomics Limited
- Ligand Pharmaceuticals
- Lupin Limited
- Novartis AG
- Pfizer Inc.
- Reddy's Laboratory
- Teva Pharmaceuticals Industries
For more information about this report visit https://www.researchandmarkets.com/research/56tkqt/global?w=4